Compounds > gemcitabine
Page last updated: 2024-08-24

gemcitabine and Abnormalities, Autosome

gemcitabine has been researched along with Abnormalities, Autosome in 9 studies

Research

Studies (9)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (11.11)18.2507
2000's6 (66.67)29.6817
2010's2 (22.22)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alanazi, KM1
Blenc, AM; Boxwala, I; Chisti, MM; Jaiyesimi, I; Micale, MA; Muslimani, A1
Aydemir, N; Bilaloğlu, R1
Ameye, G; Cedervall, B; Grégoire, V; Libouton, JM; Michaux, L; Octave-Prignot, M; Rosier, JF; Scalliet, P; Verellen-Dumoulin, C1
Castro Kreder, N; Franken, NA; Haveman, J; Van Bree, C2
Aydemir, N; Bilaloğlu, R; Celikler, S1
Bergman, AM; Costa, JL; Meijer, GA; Oudejans, CB; Peters, GJ; Smid, K; van de Wiel, MA; Ylstra, B1
Auer, H; Glössl, J; Kowalski, H; Kucera, E; Lindner, R; Oehler, R; Orel, L; Simon, MM; Sliutz, G1

Other Studies

9 other study(ies) available for gemcitabine and Abnormalities, Autosome

ArticleYear
Anti-mutagenic activity of Salvia merjamie extract against gemcitabine.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Antimutagenic Agents; Bone Marrow; Camphanes; Cells, Cultured; Chromosome Aberrations; Deoxycytidine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Gemcitabine; Male; Mice; Mitosis; Mitotic Index; Panax notoginseng; Salvia miltiorrhiza

2015
Langerhans/dendritic cell sarcoma arising from hairy cell leukemia: a rare phenomenon.
    Annals of hematology, 2012, Volume: 91, Issue:9

    Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Transdifferentiation; Chromosome Aberrations; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Gene Rearrangement, B-Lymphocyte; Humans; Hypopharyngeal Neoplasms; Immunophenotyping; Karyotyping; Langerhans Cell Sarcoma; Leukemia, Hairy Cell; Mutation; Neoplastic Stem Cells; Pyriform Sinus; Taxoids

2012
Genotoxicity of two anticancer drugs, gemcitabine and topotecan, in mouse bone marrow in vivo.
    Mutation research, 2003, May-09, Volume: 537, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Marrow Cells; Chromosome Aberrations; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Gemcitabine; Mice; Micronucleus Tests; Mitosis; Regression Analysis; Time Factors; Topotecan

2003
The radioenhancement of two human head and neck squamous cell carcinomas by 2'-2' difluorodeoxycytidine (gemcitabine; dFdC) is mediated by an increase in radiation-induced residual chromosome aberrations but not residual DNA DSBs.
    Mutation research, 2003, Jun-19, Volume: 527, Issue:1-2

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chromosome Aberrations; Combined Modality Therapy; Deoxycytidine; DNA Damage; DNA, Neoplasm; Gemcitabine; Head and Neck Neoplasms; Humans; Radiation Tolerance; Radiation-Sensitizing Agents; Radiation, Ionizing; Time Factors; Tumor Cells, Cultured

2003
Colour junctions as predictors of radiosensitivity: X-irradiation combined with gemcitabine in a lung carcinoma cell line.
    Journal of cancer research and clinical oncology, 2003, Volume: 129, Issue:10

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Chromosome Aberrations; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Flow Cytometry; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents

2003
Effects of gemcitabine on cell survival and chromosome aberrations after pulsed low dose-rate irradiation.
    Journal of radiation research, 2004, Volume: 45, Issue:1

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Chromosome Aberrations; Chromosomes; Deoxycytidine; Dose-Response Relationship, Radiation; Gemcitabine; Humans; Lung Neoplasms; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents; X-Rays

2004
In vitro genotoxic effects of the anticancer drug gemcitabine in human lymphocytes.
    Mutation research, 2005, Apr-04, Volume: 582, Issue:1-2

    Topics: Antineoplastic Agents; Cells, Cultured; Chromosome Aberrations; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphocytes; Male; Sister Chromatid Exchange

2005
Expression microarray analysis and oligo array comparative genomic hybridization of acquired gemcitabine resistance in mouse colon reveals selection for chromosomal aberrations.
    Cancer research, 2005, Nov-15, Volume: 65, Issue:22

    Topics: Animals; Antimetabolites, Antineoplastic; Chromosome Aberrations; Colonic Neoplasms; Deoxycytidine; DNA Replication; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Mice; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis

2005
Characterisation of genotoxic properties of 2',2'-difluorodeoxycytidine.
    Mutation research, 1997, Sep-18, Volume: 393, Issue:1-2

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Division; Cell Line, Transformed; Cells, Cultured; Chromosome Aberrations; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Micronucleus Tests; Mutagens; Sister Chromatid Exchange

1997